CA2647360C - Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale - Google Patents
Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale Download PDFInfo
- Publication number
- CA2647360C CA2647360C CA2647360A CA2647360A CA2647360C CA 2647360 C CA2647360 C CA 2647360C CA 2647360 A CA2647360 A CA 2647360A CA 2647360 A CA2647360 A CA 2647360A CA 2647360 C CA2647360 C CA 2647360C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- esters
- irritant
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78244806P | 2006-03-15 | 2006-03-15 | |
US60/782,448 | 2006-03-15 | ||
PCT/US2007/006519 WO2007106550A2 (fr) | 2006-03-15 | 2007-03-14 | Procédés et compositions de dissuasion d'abus de produits pharmaceutiques à administration orale |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2647360A1 CA2647360A1 (fr) | 2007-09-20 |
CA2647360C true CA2647360C (fr) | 2012-05-15 |
Family
ID=38510088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2647360A Expired - Fee Related CA2647360C (fr) | 2006-03-15 | 2007-03-14 | Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1993519A4 (fr) |
AU (1) | AU2007225101A1 (fr) |
CA (1) | CA2647360C (fr) |
IL (1) | IL193766A0 (fr) |
WO (1) | WO2007106550A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024430A1 (fr) | 2001-09-21 | 2003-03-27 | Egalet A/S | Systeme a liberation de polymere de morphine |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
EP1610767B1 (fr) | 2003-03-26 | 2011-01-19 | Egalet A/S | Systeme de liberation regulee de morphine |
NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
AU2015200313B2 (en) * | 2007-12-17 | 2016-12-01 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
BRPI0821732A2 (pt) | 2007-12-17 | 2015-06-16 | Labopharm Inc | Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada |
CA2709905A1 (fr) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Composition d'oxycodone a l'epreuve d'un usage abusif |
CA2751667C (fr) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Composition a liberation immediate resistant a une maltraitance par prise d'alcool |
EP2445487A2 (fr) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Formulations à libération contrôlée |
CA2877183A1 (fr) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Compositions pharmaceutiques de dissuasion d'abus a liberation controlee |
WO2015023675A2 (fr) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération immédiate |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
WO2016010771A1 (fr) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
-
2007
- 2007-03-14 WO PCT/US2007/006519 patent/WO2007106550A2/fr active Application Filing
- 2007-03-14 CA CA2647360A patent/CA2647360C/fr not_active Expired - Fee Related
- 2007-03-14 AU AU2007225101A patent/AU2007225101A1/en not_active Abandoned
- 2007-03-14 EP EP07753168A patent/EP1993519A4/fr not_active Withdrawn
-
2008
- 2008-08-28 IL IL193766A patent/IL193766A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
Also Published As
Publication number | Publication date |
---|---|
WO2007106550A3 (fr) | 2008-06-12 |
CA2647360A1 (fr) | 2007-09-20 |
IL193766A0 (en) | 2011-08-01 |
AU2007225101A1 (en) | 2007-09-20 |
EP1993519A4 (fr) | 2011-12-21 |
EP1993519A2 (fr) | 2008-11-26 |
WO2007106550A2 (fr) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2647360C (fr) | Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale | |
US20130005823A1 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
US20070231268A1 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
US20060110327A1 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
US20060177380A1 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
US11083794B2 (en) | Methods and compositions for self-regulated release of active pharmaceutical ingredient | |
CA2502965C (fr) | Forme galenique protegee contre un usage detourne | |
US10632113B2 (en) | Abuse-resistant drug formulations with built-in overdose protection | |
AU2004264667B2 (en) | Abuse-proofed dosage form | |
NZ545202A (en) | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide | |
AU2012201450A1 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
US20170056501A1 (en) | Methods and compositions for self-regulated release of active pharmaceutical ingredient | |
IL183362A (en) | Preparations to discourage the misuse of oral pharmaceutical products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190314 |